Skip to main content

Schuth Alexander O.'s Form 4 filing

Denali Therapeutics Inc. (DNLI) · filed Apr 14, 2023

Accession no.
0001714899-23-000055
Filed
Apr 14, 2023
Trade date
Apr 12-13, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $250.4K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Schuth Alexander O.CIK 0001724311Officer (COFO and Secretary)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Apr 12, 2023Common StockMOption exerciseAcquired+5,102$5.28+$26,938.56533,793Indirect
Apr 12, 2023Common StockSSaleDisposed−5,102$25.04F4−$127,754.08528,691Indirect
Apr 13, 2023Common StockMOption exerciseAcquired+4,898$5.28+$25,861.44533,589Indirect
Apr 13, 2023Common StockSSaleDisposed−4,898$25.04F5−$122,645.92528,691Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Apr 12, 2023Common StockMOption exerciseDisposed−5,102$0.00$093,835Direct
Apr 13, 2023Common StockMOption exerciseDisposed−4,898$0.00$088,937Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F4

The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $25.00 to $25.49 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

F5

The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $25.00 to $25.10 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)